Please login to the form below

Not currently logged in
Email:
Password:

Pharmalink appoints Dr Heather Cook and Marek Poszepczynski

Strengthens senior management team

Pharmalink Marek PoszepczynskiPharmalink has bolstered its senior management team with the appointment of Dr Heather Cook and Marek Poszepcynski (pictured).

Dr Cook joins the Swedish specialty pharmaceutical company as director of regulatory affairs from Lundbeck, where she headed up its regulatory development projects department.

Prior to her time with Lundbeck, Dr Cook served at AstraZeneca as its global regulatory affairs director for oncology and a number of other senior roles, including scientific director for neuroscience and infection.

Pharmalink's other senior management appointment is Marek Poszepcynski who takes up the role of director of business development.

He arrives at the company from analysts Handelsbanken, where he covered European and Swedish biotechnology stocks, and before that was vice president of business development at Karolinska Development.

Pharmalink's managing director Johan Häggblad said: "These appointments add significant talent and new experience to Pharmalink's management team as the company continues to drive forward its late stage clinical development programs for Nefecon and Busulipo and actively seeks new product opportunities.

“It is a measure of our reputation that such high caliber executives have joined us and I look forward to working with Heather and Marek through what is an exciting stage of development."

Picture credit: Lenita Gahlin

30th October 2012

From: Sales, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Life Brands Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

Growing influence of pharmacists in the sale of Rx and OTC medicines
Find out how the changes within pharmacy have affected their influence over the sales of RX and OTC medicines in this whitepaper....
Drivers of 2014′s Soaring Drug Approvals
The FDA & EMA approved a chart-topping number of new drugs in 2014. Read more in our White Paper about the responsibility this growing approval success will put on future...
Russian innovation at the crossroads
Despite improvements, investors face rising risks...